医学
帕博西利布
富维斯特朗
转移性乳腺癌
肿瘤科
内科学
不利影响
乳腺癌
癌症
毒性
中性粒细胞减少症
三苯氧胺
作者
Demi Wekking,Matteo Lambertini,Mariele Dessì,Nerina Denaro,Fabio Bardanzellu,Ornella Garrone,Mario Scartozzi,Cinzia Solinas
标识
DOI:10.1053/j.seminoncol.2024.01.002
摘要
The development of oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (BC). When combined with an aromatase inhibitor or fulvestrant, these agents have been approved as first-line therapy in the metastatic setting. Abemaciclib has also gained FDA approval for patients with HR-positive, HER2-negative, node-positive, early BC at high risk of recurrence. Moreover, ribociclib has recently improved disease-free survival in patients with stage II or III HR+/HER2-negative early BC. CDK4/6 inhibitors have favorable safety profiles. However, the available agents have different toxicity profiles that must be clearly discussed with the patients for optimal clinical decisions. This manuscript aims to review CDK4/6 inhibitor-related treatment-associated adverse events, identify risk factors for intolerable adverse events, and assess their safety in special patient populations such as the elderly and those with renal insufficiency. Enhanced knowledge and understanding of CDK4/6 inhibitor-related toxicities can improve treatment strategies and ultimately enhance patient care.
科研通智能强力驱动
Strongly Powered by AbleSci AI